Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...
Findings showed darolutamide reduced the risk of radiographic progression or death by 46% compared with placebo. The Food and Drug Administration (FDA) has approved Nubeqa ® (darolutamide), an ...
Prostate cancer is the most prevalent cancer in men worldwide. As new treatments become available, costs also increase, and patients from lower-middle-income countries do not have access to those ...
Role of urinary exosomal FAM153C-RPL19 in detection and risk stratification of prostate cancer: A multicentre Chinese cohort study. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...
Metastatic prostate cancer is also referred to as stage 4 or advanced prostate cancer. It's cancer that began in the prostate, a gland located under the bladder of people assigned male at birth, and ...